Fly News Breaks for March 2, 2020
Mar 2, 2020 | 08:10 EDT
Jefferies analyst Michael Yee initiated coverage of Schrodinger with a Hold rating and $42 price target. While he sees the company having a "growing and powerful" life sciences drug software business, a proprietary pipeline of more than 5 cancer drugs entering the clinic that "could be blockbusters" and royalties and equity in over 20 other partner drugs, he believes all of this may be priced in with the stock up 150%-200% since the company's IPO, Yee tells investors.
News For SDGR From the Last 2 Days
There are no results for your query SDGR